趙清華 孫 旭 朱澤章 王 斌 俞 楊 錢邦平 劉 臻 邱 勇
(南京醫(yī)科大學(xué)鼓樓臨床醫(yī)學(xué)院脊柱外科,南京 210008)
·臨床研究·
O-arm導(dǎo)航經(jīng)皮椎體成形術(shù)治療癥狀性椎體血管瘤*
趙清華 孫 旭 朱澤章 王 斌 俞 楊 錢邦平 劉 臻 邱 勇**
(南京醫(yī)科大學(xué)鼓樓臨床醫(yī)學(xué)院脊柱外科,南京 210008)
目的 探討應(yīng)用O-arm導(dǎo)航系統(tǒng)行經(jīng)皮椎體成形術(shù)(percutaneous vertebroplasty,PVP)治療癥狀性椎體血管瘤的安全性和療效。方法選取2014年1月~2015年7月應(yīng)用O-arm導(dǎo)航系統(tǒng)行PVP 9例(11椎)癥狀性椎體血管瘤臨床資料。男3例,女6例,年齡(54.7±11.0)歲(36~70歲)。記錄手術(shù)時(shí)間、骨水泥注射量、術(shù)后并發(fā)癥。術(shù)后第2天復(fù)查X線及CT評(píng)估骨水泥滲漏情況。比較術(shù)前、術(shù)后第2天及末次隨訪病椎椎體高度。術(shù)前及術(shù)后3天、末次隨訪用視覺模擬評(píng)分(visual analogue scale,VAS)評(píng)估疼痛情況。結(jié)果單側(cè)椎弓根注射骨水泥7個(gè)椎體,雙側(cè)椎弓根注射骨水泥4個(gè)椎體,每椎骨水泥注射量(3.3±0.7)ml(2.5~4.5 ml),每椎手術(shù)時(shí)間(38.2±8.1)min(30~50 min)。術(shù)后第2天X線、CT顯示骨水泥填充病灶良好,分布均勻,1例有病椎前緣少量骨水泥滲漏。均未出現(xiàn)神經(jīng)損傷、肺栓塞等并發(fā)癥。術(shù)后隨訪(6.6±4.2)月(3~15個(gè)月),未發(fā)現(xiàn)病椎塌陷和腫瘤復(fù)發(fā)。術(shù)后VAS評(píng)分逐漸下降,術(shù)前VAS評(píng)分(5.9±0.8)分,術(shù)后第3天(2.4±1.1)分,末次隨訪(0.4±0.7)分,兩兩比較均存在統(tǒng)計(jì)學(xué)差異(P<0.05)。術(shù)前、術(shù)后第2天及末次隨訪病椎椎體高度均無統(tǒng)計(jì)學(xué)差異(P>0.05)。結(jié)論應(yīng)用O-arm導(dǎo)航系統(tǒng)可達(dá)到精確經(jīng)皮穿刺,在其導(dǎo)航下行PVP治療癥狀性椎體血管瘤是一種創(chuàng)傷小、安全有效的方法。
O-arm導(dǎo)航系統(tǒng); 經(jīng)皮椎體成形術(shù); 癥狀性椎體血管瘤
椎體血管瘤是一種常見的良性血管源性骨腫瘤,通常沒有臨床癥狀,無需處理[1]。癥狀性椎體血管瘤通常表現(xiàn)為背痛,部分患者甚至進(jìn)展為侵襲脊髓和神經(jīng)根,引起神經(jīng)癥狀,此類患者通常需手術(shù)治療。傳統(tǒng)治療包括放射治療、無水酒精注射及手術(shù)切除等,但均存在脊髓缺血壞死、病理性骨折及創(chuàng)傷大等缺點(diǎn)[2~5]。經(jīng)皮椎體成形術(shù)(percutaneous vertebroplasty,PVP)近年用于癥狀性椎體血管瘤的治療,并取得了良好的療效[6,7]。但由于PVP手術(shù)操作在C形臂X線機(jī)下完成,存在放射暴露時(shí)間長(zhǎng)、穿刺損傷血管神經(jīng)以及骨水泥滲漏等風(fēng)險(xiǎn)[8]。自20世紀(jì)90年代以來,計(jì)算機(jī)輔助骨科手術(shù)技術(shù)應(yīng)用于臨床,使手術(shù)操作更加精確、微創(chuàng)、安全。O-arm導(dǎo)航系統(tǒng)能夠在術(shù)中實(shí)時(shí)提供二維或三維圖像,精確指導(dǎo)術(shù)者完成手術(shù)操作。2014年1月~2015年7月,我科開展O-arm導(dǎo)航系統(tǒng)輔助PVP治療9例(11椎)癥狀性脊柱血管瘤,療效滿意,現(xiàn)報(bào)道如下。
1.1 一般資料
本組9例,男3例,女6例。年齡36~70歲,(54.7±11.0)歲。均有胸腰背部頑固性疼痛,病程3~36個(gè)月,(13.3±10.4)月,經(jīng)藥物及休息等保守治療無效。均行CT及MRI檢查,符合椎體血管瘤表現(xiàn),2例同時(shí)存在2個(gè)部位血管瘤,共11個(gè)椎體,T61個(gè),T71個(gè),T91個(gè),T112個(gè),T122個(gè),L13個(gè),L21個(gè)。9例均為單純性癥狀性椎體血管瘤。1例術(shù)前發(fā)生椎體壓縮性骨折。
納入標(biāo)準(zhǔn):血管瘤位于胸椎或腰椎;血管瘤完全位于椎體內(nèi),且椎體后緣保持完整;無椎管內(nèi)累及或神經(jīng)損害癥狀。
1.2 手術(shù)方法
全麻,患者俯臥于Jackson可透視床上。所有操作均在神經(jīng)監(jiān)護(hù)儀監(jiān)測(cè)下進(jìn)行。在O-arm導(dǎo)航系統(tǒng)(美國(guó)Medtronic公司)下手術(shù)。先采用O-arm二維模式,攝脊柱正側(cè)位片確定病椎。于病椎近端隔2節(jié)椎體處做2 cm切口,顯露棘突,將參考架固定于棘突上(圖1A)。啟動(dòng)O-arm三維掃描模式,針對(duì)病椎通過O形臂旋轉(zhuǎn)360°采集的圖像,建立三維影像,并向StealthStation S7工作站(美國(guó)Medtronic公司)傳輸數(shù)據(jù)(圖1B)。連接有主動(dòng)參考架的椎弓根穿刺針經(jīng)工作站注冊(cè)后,在三維影像導(dǎo)航引導(dǎo)下,選擇最佳的進(jìn)針點(diǎn)和椎弓根進(jìn)針軌跡(圖1C、D)。當(dāng)穿刺針到達(dá)椎體前中1/3處后,置入套管。緩慢將漿糊期的骨水泥(聚甲基丙烯酸甲酯polymethymethacrylate,PMMA,意大利Tecres公司)沿套筒推入椎體內(nèi)。推注骨水泥過程中,在側(cè)位持續(xù)透視監(jiān)控下觀察骨水泥彌散情況,防止骨水泥滲漏至椎旁血管、椎間隙、肌肉組織或椎管內(nèi)。若瘤體填充不滿,則按照上述方法沿對(duì)側(cè)椎弓根推注。術(shù)后行心電監(jiān)護(hù)監(jiān)測(cè)生命體征30 min,安返病房后平臥休息24 h,觀察有無并發(fā)癥。
1.3 術(shù)后療效評(píng)估及隨訪
術(shù)前、術(shù)后3天及末次隨訪采用視覺疼痛評(píng)分法(visual analogue scales,VAS)評(píng)估患者疼痛緩解情況,0分為不痛,10分為最痛。術(shù)后第2天行脊柱正側(cè)位X線片及CT檢查,評(píng)估骨水泥分布及滲漏、瘤體填充情況。在脊柱側(cè)位片上測(cè)量病椎椎體前緣高度,對(duì)比術(shù)前、術(shù)后第2天及末次隨訪的變化。
1.4 統(tǒng)計(jì)學(xué)方法
見表1、2。9例11椎體癥狀性椎體血管瘤患者行PVP手術(shù),其中單側(cè)椎弓根注射骨水泥7個(gè)椎體,雙側(cè)椎弓根注射骨水泥4個(gè)椎體,每椎骨水泥注射量(3.3±0.7)ml,每椎手術(shù)時(shí)間(38.2±8.1)min。均無術(shù)中死亡,無肺栓塞、心腦血管系統(tǒng)急性反應(yīng)、神經(jīng)根或脊髓損傷以及感染等。術(shù)后第2天X線、CT顯示骨水泥填充病灶良好,分布均勻(圖2),1例病椎前緣少量骨水泥滲漏,無血管神經(jīng)并發(fā)癥發(fā)生。術(shù)后隨訪3~15個(gè)月,(6.6±4.2)月,癥狀均明顯改善,末次隨訪7例疼痛完全緩解,2例殘余輕微腰背部疼痛。術(shù)后VAS評(píng)分呈下降趨勢(shì),術(shù)前、術(shù)后3天、末次隨訪差異均有顯著性(P<0.05)。椎體高度術(shù)前、術(shù)后3天、末次隨訪差異無顯著性(P>0.05)。均未發(fā)現(xiàn)病椎塌陷、相鄰椎體骨折及血管瘤復(fù)發(fā)。
表1 9例癥狀性椎體血管瘤患者PVP資料
表2 術(shù)前與術(shù)后不同時(shí)間點(diǎn)VAS評(píng)分、病椎椎體前緣高度的比較
圖1 O-arm導(dǎo)航系統(tǒng)的應(yīng)用 A:于病椎近端隔2節(jié)椎體處做2 cm切口,顯露棘突,將參考架固定于棘突上;B:?jiǎn)?dòng)O-arm三維掃描模式,針對(duì)病椎通過O形臂旋轉(zhuǎn)360°采集的圖像,建立三維影像,并向StealthStation S7工作站傳輸數(shù)據(jù);C、D:連接有主動(dòng)參考架的椎弓根穿刺針經(jīng)工作站注冊(cè)后,在三維影像導(dǎo)航引導(dǎo)下,選擇最佳的進(jìn)針點(diǎn)和椎弓根進(jìn)針軌跡 圖2 患者女,52歲,因“胸腰背部頑固性疼痛半年余”入院,診斷為T11椎體血管瘤。CT(A):T11橫斷面顯示骨小梁呈點(diǎn)狀增粗,血管瘤局限在椎體內(nèi),未累及椎體附件,椎體邊緣光整。側(cè)位X線片(B):T11椎體內(nèi)部隱約可見部分骨小梁吸收。MRI的T1W(C)、T2W(D)示病變椎體信號(hào)均高于正常椎體。術(shù)后第2天CT(E、F)橫斷面及矢狀面上,病灶填充良好,骨水泥未突破椎體周圍皮質(zhì)
脊柱血管瘤是脊柱常見的良性腫瘤,尸檢發(fā)現(xiàn)率約為11.9%,好發(fā)于青少年,以胸椎、腰椎多見[9]。多數(shù)患者無臨床癥狀,偶因行影像學(xué)檢查發(fā)現(xiàn),常不需特殊治療。少數(shù)呈膨脹性生長(zhǎng),破壞骨皮質(zhì)甚至壓迫神經(jīng),表現(xiàn)為單純的背部疼痛伴或不伴神經(jīng)功能損害[10]。自1987年Galibert等[11]首次成功應(yīng)用PVP治療癥狀性椎體血管瘤以來,PVP治療椎體血管瘤得到廣泛應(yīng)用。既往研究表明其具有創(chuàng)傷小,能有效緩解疼痛,增加椎體穩(wěn)定性等特點(diǎn)[12]。PVP鎮(zhèn)痛機(jī)制可能為:骨水泥使微小骨折得到固定,增加了椎體穩(wěn)定性;骨水泥聚合時(shí)散發(fā)的高能量及其毒性作用可能破壞了椎體內(nèi)的炎性致痛因子和感覺神經(jīng)末梢,從而達(dá)到止痛效果;腫瘤血管可受到骨水泥壓迫和灼燒,直接缺血壞死[13]。本組均存在胸腰背部頑固性疼痛,有手術(shù)指征,PVP術(shù)后VAS評(píng)分明顯減低,疼痛均得到明顯緩解,經(jīng)過平均6.6月隨訪,7例疼痛完全緩解,2例只殘余少量腰背部疼痛,未出現(xiàn)病灶塌陷及鄰近椎體骨折,血管瘤無復(fù)發(fā)。
3.1 傳統(tǒng)PVP治療椎體血管瘤的精確性和安全性
成功穿刺入瘤體并保持穿刺通道完整是PVP手術(shù)治療椎體血管瘤的關(guān)鍵。傳統(tǒng)PVP手術(shù)的穿刺定位及骨水泥注入等操作在C形臂X線機(jī)下進(jìn)行,由于脊柱復(fù)雜的結(jié)構(gòu)以及毗鄰血管神經(jīng),加之可能存在的脊柱側(cè)凸、旋轉(zhuǎn)、椎弓根過細(xì)等情況,穿刺角度和深度難以精確把握,常需反復(fù)多次穿刺才能建立理想通道。一旦穿破椎弓根壁進(jìn)入椎管內(nèi),或穿破椎體前緣,就可能損傷脊髓神經(jīng)和血管,同時(shí)破壞了椎體皮質(zhì)的完整性,增加骨水泥滲漏的發(fā)生率。同時(shí),由于血管瘤在椎體內(nèi)分布的局限性,穿刺不精確可能使骨水泥難以進(jìn)入瘤體內(nèi),達(dá)不到治療的目的。PVP最常見的并發(fā)癥是骨水泥滲漏,其發(fā)生率為9%~74%[14],盡管大多數(shù)滲漏無臨床癥狀,但嚴(yán)重時(shí)可引起肺栓塞、脊髓神經(jīng)損傷[15,16]。Liu等[7]對(duì)26例33椎癥狀性椎體血管瘤行PVP,4椎(12.1%)出現(xiàn)骨水泥滲漏,未出現(xiàn)神經(jīng)血管損傷、肺栓塞等并發(fā)癥。椎體皮質(zhì)不完整可增加PVP術(shù)中發(fā)生骨水泥滲漏的風(fēng)險(xiǎn)。張繼等[17]報(bào)道4例癥狀性血管瘤PVP術(shù)中發(fā)生骨水泥滲漏患者術(shù)前椎體均發(fā)生壓縮性骨折,這可能與骨折破壞了椎體完整性有關(guān)。C形臂X線機(jī)只能獲得單一平面的影像,術(shù)中定位時(shí)需在正位及側(cè)位上反復(fù)多次投照,造成手術(shù)中斷,不僅增加手術(shù)時(shí)間,也大大增加了術(shù)中患者和醫(yī)護(hù)人員的放射暴露[18]。因此,傳統(tǒng)PVP已不能滿足當(dāng)前脊柱外科向精準(zhǔn)化發(fā)展的需要。
3.2 O-arm導(dǎo)航下行PVP治療椎體血管瘤的優(yōu)勢(shì)
近年來,手術(shù)導(dǎo)航技術(shù)因具有微創(chuàng)、高精度、低輻射暴露等優(yōu)點(diǎn),在脊柱外科手術(shù)中得到廣泛應(yīng)用。目前在脊柱手術(shù)中應(yīng)用較多的導(dǎo)航系統(tǒng)有基于X線透視技術(shù)的二維導(dǎo)航和基于術(shù)前CT掃描的三維導(dǎo)航等,但前者存在精度低等缺陷[17],后者存在注冊(cè)繁瑣、實(shí)時(shí)性差、配準(zhǔn)難度大、動(dòng)態(tài)基準(zhǔn)易松動(dòng)等缺點(diǎn)[19],給臨床應(yīng)用帶來不便。美敦力公司O-arm導(dǎo)航系統(tǒng)能在術(shù)中1 min內(nèi)完成高質(zhì)量二維采集、三維圖像重建和傳輸,自動(dòng)注冊(cè),圖像傳輸完畢即可直接手術(shù),并實(shí)時(shí)跟蹤手術(shù)器械及其對(duì)應(yīng)解剖結(jié)構(gòu),使術(shù)者能精確完成操作。相對(duì)于傳統(tǒng)PVP,O-arm導(dǎo)航下行PVP治療椎體血管瘤具有以下優(yōu)點(diǎn):①能夠精確穿刺,避免在建立通道過程中因反復(fù)穿刺帶來的椎弓根破裂等風(fēng)險(xiǎn),進(jìn)而減低骨水泥滲出幾率。Sembrano等[20]比較O-arm導(dǎo)航系統(tǒng)和C形臂X線機(jī)定位下椎體后凸成形術(shù)治療骨質(zhì)疏松性椎體壓縮性骨折,結(jié)果顯示C形臂X線組探針誤置率為27%(3/11),而O-arm導(dǎo)航組為3%(1/36)。O-arm導(dǎo)航下精確穿刺降低了椎弓根、椎體壁的破裂幾率,進(jìn)而減少骨水泥滲漏的發(fā)生。Schils等[21]報(bào)道54例O-arm導(dǎo)航下行椎體后凸成形術(shù)治療椎體血管瘤,均未出現(xiàn)骨水泥滲漏。本組9例11椎術(shù)中穿刺位置精確,未發(fā)現(xiàn)椎弓根壁破裂,骨水泥填充病灶良好,分布均勻。1例椎體前方骨水泥滲漏,可能是由于該患者術(shù)前椎體已存在輕微壓縮性骨折導(dǎo)致椎體前方皮質(zhì)不完整。② O-arm導(dǎo)航能同時(shí)提供二維、三維圖像,大大減少使用C形臂X線機(jī)時(shí)反復(fù)投照的次數(shù),從而減少手術(shù)時(shí)間以及患者和醫(yī)護(hù)人員的射線暴露。Schils等[21]報(bào)道54例O-arm導(dǎo)航下行椎體后凸成形術(shù),單椎平均手術(shù)時(shí)間、透視時(shí)間和輻射量分別為38 min、2.5 min和166 mGy,均明顯少于C形臂X線機(jī),認(rèn)為O-arm導(dǎo)航相比傳統(tǒng)C形臂X線機(jī)具有節(jié)省手術(shù)時(shí)間、減少患者和醫(yī)護(hù)人員放射暴露、增加手術(shù)精度等優(yōu)點(diǎn)。本組9例11椎單椎平均手術(shù)時(shí)間38.2 min,Hao等[22]報(bào)道26例28椎采用C形臂X線機(jī)定位下行PVP治療椎體血管瘤的平均手術(shù)時(shí)間為40 min。③如懷疑有骨水泥向椎管內(nèi)滲漏,可在術(shù)中立即行O-arm三維掃描,觀察骨水泥在椎管內(nèi)分布及向椎管內(nèi)滲漏情況,以便能及時(shí)處理可能對(duì)脊髓、神經(jīng)根造成的壓迫,同時(shí)也避免術(shù)后再次行放射性影像學(xué)檢查。
綜上所述,采用O-arm導(dǎo)航系統(tǒng)引導(dǎo)行PVP手術(shù)治療椎體血管瘤,術(shù)中能在三維圖像上實(shí)時(shí)觀察穿刺針行進(jìn)的位置,實(shí)現(xiàn)精準(zhǔn)穿刺和骨水泥注射,提高手術(shù)精度,縮短手術(shù)時(shí)間,減少射線暴露,是安全有效的治療癥狀性椎體血管瘤的微創(chuàng)方法,具有廣闊的應(yīng)用前景。
1 Acosta FL,Dowd CF,Chin C,et al.Current treatment strategies and outcomes in the management of symptomatic vertebral hemangiomas.Neurosurgery,2006,58(2):287-295.
2 Mazonakis M,Tzedakis A,Lyraraki E,et al.Radiation dose and cancer risk to out-of-field and partially in-field organs from radiotherapy for symptomatic vertebral hemangiomas.Med Phys,2016,43(4):1841.
3 Cianfoni A,Massari F,Dani G,et al.Percutaneous ethanol embolization and cement augmentation of aggressive vertebral hemangiomas at two adjacent vertebral levels.J Neuroradiol,2014,41(4):269-274.
4 Prabhakar H,Singh GP.Absolute alcohol embolization of symptomatic vertebral hemangiomas may not be absolutely safe during intraoperative period!Neurosurgery,2011,69(2):E502.
5 Kawahara N,Tomita K,Murakami H,et al.Total en bloc spondylectomy of the lower lumbar spine:a surgical techniques of combined posterior-anterior approach.Spine (Phila Pa 1976),2011,36(1):74-82.
6 楊益民,張 智,李 萌,等.經(jīng)皮穿刺椎體后凸成形術(shù)在癥狀性椎體血管瘤中的應(yīng)用.中國(guó)微創(chuàng)外科雜志,2013,13(10):906-909.
7 Liu XW,Jin P,Wang LJ,et al.Vertebroplasty in the treatment of symptomatic vertebral haemangiomas without neurological deficit.Eur Radiol,2013,23(9):2575-2581.
8 Layton KF,Thielen KR,Koch CA,et al.Vertebroplasty,first 1000 levels of a single center: evaluation of the outcomes and complications.AJNR Am J Neuroradiol,2007,28(4):683-689.
9 Slon V,Stein D,Cohen H,et al.Vertebral hemangiomas:their demographical characteristics,location along the spine and position within the vertebral body.Eur Spine J,2015,24(10):2189-2195.
10 Urrutia J,Postigo R,Larrondo R,et al.Clinical and imaging findings in patients with aggressive spinal hemangioma requiring surgical treatment.J Clin Neurosci,2011,18(2):209-212.
11 Galibert P,Deramond H,Rosat P,et al.Preliminary note on the treatment of vertebral angioma by percutaneous acrylic vertebroplasty.Neurochirurgie,1987,33(2):166-168.
13 Evans AJ,Jensen ME,Kip KE,et al.Vertebral compression fractures:pain reduction and improvement in functional mobility after percutaneous polymethylmethacrylate vertebroplasty retrospective report of 245 cases.Radiology,2003,226(2):336-372.
14 Chen CH,Chuang MT,Wang CK.Intradural cement leakage after vertebroplasty.Spine J,2015,15(6):1493-1494.
15 張功林,葛寶豐.經(jīng)皮椎體成形術(shù)的并發(fā)癥.中國(guó)骨傷,2013,26(3):257-260.
16 Petridis AK,Maslehaty H,Eichenhofer T,et al.Pulmonary embolism associated with poly (methyl methacrylate) (PMMA) after vertebroplasty.A complication more often than one thinks.Acta Neurochirurgica,2013,155(2):319-320.
17 張 繼,吳春根,程永德,等.經(jīng)皮椎體成形術(shù)治療癥狀性椎體血管瘤遠(yuǎn)期療效分析.介入放射學(xué)雜志,2007,16(10):676-680.
18 Nolte LP,Beutler T.Basic principles of CAOS.Injury,2004,35 Suppl 1:S-A6-16.
19 Braun V,Rath SA,Antoniadis G,et al.In vivo experiences with frameless stereotactically guided screw placement in the spine-results from 75 consecutive cases.Neurosurg Rev,2001,24(2-3):74-79.
20 Sembrano JN,Yson SC,Polly DW Jr,et al.Comparison of nonnavigated and 3-dimensional image-based computer navigated balloon kyphoplasty.Orthopedics,2015,38(1):17-23.
21 Schils F.O-arm-guided balloon kyphoplasty:prospective single-center case series of 54 consecutive patients.Neurosurgery,2011,68(2 Suppl Operative):ons250-256.
22 Hao J,Hu Z.Percutaneous cement vertebroplasty in the treatment of symptomatic vertebral hemangiomas.Pain Physician,2012,15(1):43-49.
(修回日期:2016-07-06)
(責(zé)任編輯:王惠群)
O-arm-guided Percutaneous Vertebroplasty in the Treatment of Symptomatic Vertebral Hemangioma
ZhaoQinghua,SunXu,ZhuZezhang,etal.
DepartmentofSpinalSurgery,NanjingDrumTowerHospital,ClinicalCollegeofNanjingMedicalUniversity,Nanjing210008,China
QiuYong,E-mail:scoliosis2002@sina.com
O-arm-guided navigation; Percutaneous vertebroplasty; Vertebral hemangioma
國(guó)家自然科學(xué)基金(項(xiàng)目編號(hào):81401848)
**通訊作者,E-mail:scoliosis2002@sina.com
A
1009-6604(2016)10-0917-05
10.3969/j.issn.1009-6604.2016.10.014
2016-03-15)
【Summary】 Objective To evaluate the effectiveness of O-arm-guided percutaneous vertebroplasty (PVP) in the treatment of symptomatic vertebral hemangioma (VH). Methods A retrospective study was conducted on 9 consecutive patients (3 males and 6 females; mean age, 54.7±11.0 years old) with symptomatic VH who underwent O-arm-guided PVP procedures, for a total of 11 affected vertebral levels, from January 2014 to July 2015. The operative time, dose of cement and postoperative complications were recorded. Cement leakage was evaluated by X-ray and CT scan on the 2nd day postoperatively. Meanwhile, the changes of preoperative and 2nd day postoperative and final follow-up vertebral body height were compared. The clinical effects were evaluated with the visual analog scale (VAS) before surgery, 3 days after surgery and at final follow-up. Results PVP was successfully performed under O-arm guidance via a unipedicular approach in 7 levels and a bipedicular approach in 4 levels. The mean dose of bone cement was (3.3±0.7) ml (range, 2.5-4.5 ml), and the mean operative time was (38.2±8.1) minutes (range, 30-50 min). Post-operative X-ray and CT scan indicated that the bone cement filling was uniformly distributed. However, we found paravertebral cement leakage in 1 case without any onset of radicular symptoms related to epidural diffusion. No pulmonary embolism occurred and no clinical and symptomatic complications were observed. No vertebral collapse or recurrence of hemangioma was found after (6.6±4.2) months (rang,3-15 months) of followed-up. The VAS scores were significantly decreased from (5.9±0.8) points preoperatively to (2.4±1.1) points on the 3rd day postoperatively, with a final score of (0.4±0.7) points (P<0.05). No significant differences were found among the preoperative, 2nd day postoperative, and final follow-up in the height of diseased vertebra (P>0.05).Conclusions O-arm-guided PVP allows for accurate vertebral body access and cement deposition. As a minimally invasive procedure, it provides an effective and safe technique in the treatment of symptomatic VH.